Shares of Illumina Inc. (NASDAQ:ILMN) rose 3.5% during trading on Thursday . The company traded as high as $182.67 and last traded at $175.00, with a volume of 5,069,324 shares traded. The stock had previously closed at $169.15.

ILMN has been the subject of a number of analyst reports. Citigroup Inc. restated a “buy” rating and issued a $210.00 price target on shares of Illumina in a research report on Friday, April 22nd. Stifel Nicolaus restated a “buy” rating and issued a $160.00 price target (down previously from $215.00) on shares of Illumina in a research report on Wednesday, May 4th. Nomura reduced their price target on Illumina from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, May 3rd. CL King initiated coverage on Illumina in a research report on Tuesday, June 21st. They issued a “buy” rating and a $165.00 price target for the company. Finally, Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $167.08 price target for the company. in a research report on Monday, July 18th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $165.49.

The company has a 50-day moving average of $155.39 and a 200-day moving average of $150.14. The stock has a market cap of $25.27 billion and a P/E ratio of 59.03.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.13. During the same quarter in the prior year, the firm earned $0.80 earnings per share. The company had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. Analysts predict that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.

In other news, EVP Christian O. Henry sold 716 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $141.89, for a total transaction of $101,593.24. Following the transaction, the executive vice president now directly owns 18,976 shares in the company, valued at approximately $2,692,504.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director A Blaine Bowman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $135.08, for a total value of $675,400.00. Following the transaction, the director now owns 20,704 shares in the company, valued at $2,796,696.32. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently modified their holdings of ILMN. Calvert Investment Management Inc. boosted its position in shares of Illumina by 21.2% in the fourth quarter. Calvert Investment Management Inc. now owns 7,137 shares of the life sciences company’s stock valued at $1,370,000 after buying an additional 1,247 shares in the last quarter. I.G. Investment Management LTD. boosted its position in Illumina by 0.8% in the fourth quarter. I.G. Investment Management LTD. now owns 49,382 shares of the life sciences company’s stock worth $9,479,000 after buying an additional 414 shares in the last quarter. State of Tennessee Treasury Department acquired a new position in Illumina during the fourth quarter worth approximately $18,274,000. Stephens Investment Management Group LLC boosted its position in Illumina by 2.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 129,835 shares of the life sciences company’s stock worth $24,921,000 after buying an additional 3,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Illumina by 103.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 382,838 shares of the life sciences company’s stock worth $73,484,000 after buying an additional 194,250 shares in the last quarter.

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.